

## RITA Medical Systems to Present at Rodman & Renshaw Techvest Healthcare Conference

MOUNTAIN VIEW, Calif., Oct 26, 2004 /PRNewswire-FirstCall via COMTEX/ -- RITA Medical Systems, Inc. (Nasdaq: RITA), a medical oncology device company, today announced that President and CEO Joseph M. DeVivo is scheduled to make an investor presentation at the Rodman & Renshaw 6th Annual Techvest Healthcare Conference on Thursday, October 28, 2004 at 8:20 a.m. Eastern Time. The conference runs from October 26-28, 2004 at The Waldorf Astoria in New York City.

DeVivo will be presenting on behalf of the Company, providing an overview on the recent merger, advances in product development and sales and marketing initiatives for the coming year.

A live webcast of the Company's presentation at the Rodman & Renshaw Conference will be available via a link provided at [www.rodmanandrenshaw.com](http://www.rodmanandrenshaw.com). Go to the Rodman & Renshaw Techvest Healthcare Conference section/Conference Webcasting and click on RITA Medical Systems. An archive of the presentation will begin shortly after the presentation and will be available for thirty days.

About RITA Medical Systems, Inc.

RITA Medical Systems develops manufactures and markets innovative products for cancer patients including radiofrequency ablation (RFA) systems for treating cancerous tumors as well as percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary VTX® technology; tunneled central venous catheters; and stem-cell transplant catheters used primarily in cancer treatment protocols. The proprietary RITA system uses radiofrequency energy to heat tissue to a high enough temperature to ablate it or cause cell death. In March 2000, RITA became the first RFA Company to receive specific FDA clearance for unresectable liver lesions in addition to its previous general FDA clearance for the ablation of soft tissue. In October 2002, RITA again became the first company to receive specific FDA clearance, this time, for the palliation of pain associated with metastatic lesions involving bone.

The statements in this news release related to the use of the Company's technology and the Company's future financial and operating performance are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Information regarding these risks is included in the Company's filings with the Securities and Exchange Commission.

For further information, please contact: Investors, Jill Bertotti, [jill@allencaron.com](mailto:jill@allencaron.com), or Media, Len Hall, [len@allencaron.com](mailto:len@allencaron.com), both of Allen & Caron Inc, +1-949-474-4300, for RITA Medical Systems, Inc.; or Don Stewart, Chief Financial Officer, [dstewart@ritamed.com](mailto:dstewart@ritamed.com), or Stephen Pedroff, VP Marketing Communications, [spedroff@ritamed.com](mailto:spedroff@ritamed.com), both of RITA Medical Systems, Inc., +1-650-314-3400.

SOURCE RITA Medical Systems, Inc.

Investors, Jill Bertotti, [jill@allencaron.com](mailto:jill@allencaron.com), or Media, Len Hall, [len@allencaron.com](mailto:len@allencaron.com), both of Allen & Caron Inc, +1-949-474-4300, for RITA Medical Systems, Inc.; or Don Stewart, Chief Financial Officer, [dstewart@ritamed.com](mailto:dstewart@ritamed.com), or Stephen Pedroff, VP Marketing Communications, [spedroff@ritamed.com](mailto:spedroff@ritamed.com), both of RITA Medical Systems, Inc., +1-650-314-3400

<http://www.rodmanandrenshaw.com>